Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes.
about
How to manage aspergillosis in non-neutropenic intensive care unit patientsBurden and treatment patterns of invasive fungal infections in hospitalized patients in the Middle East: real-world data from Saudi Arabia and Lebanon.Innate Lung Defense during Invasive Aspergillosis: New Mechanisms.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Divergent targets of Aspergillus fumigatus AcuK and AcuM transcription factors during growth in vitro versus invasive diseaseEpidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomesHow to treat fungal infections in ICU patients.Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patientsPolymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium.Does galactomannan testing increase diagnostic accuracy for IPA in the ICU? A prospective observational study.Challenges in microbiological diagnosis of invasive Aspergillus infections.Histopathological implications of Aspergillus infection in lung.Republished: The clinical spectrum of pulmonary aspergillosis.Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Invasive mould infections in the ICU setting: complexities and solutions.Clinical factors affecting costs in patients receiving systemic antifungal therapy in intensive care units in Greece: Results from the ESTIMATOR study.Immune-Response Patterns and Next Generation Sequencing Diagnostics for the Detection of Mycoses in Patients with Septic Shock-Results of a Combined Clinical and Experimental Investigation.Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients.The Changing Epidemiology of Invasive Fungal Infections.Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany.Epidemiology, clinical characteristics, and outcome of invasive aspergillosis in renal transplant patients.A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation.The role of galactomannan testing to diagnose invasive pulmonary aspergillosis in critically ill patients.Clinical outcome and prognostic factors associated with invasive pulmonary aspergillosis: An 11-year follow-up report from Taiwan.Editorial Commentary: Toward New Tools to Assess Rare Invasive Fungal Diseases in Critically Ill Patients.[Aspergillus in airway material : Ignore or treat?]Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review.
P2860
Q26999448-35DC9C7B-0DAC-486C-B8E2-6DAEEE83B94FQ31162323-BED24D72-DA5E-49E1-A98D-360D9CBD822DQ33810700-57D5E0C3-987C-4739-8238-383BD3EF4271Q34532546-45D57EEC-4D9A-4E84-878A-C8346E215DCDQ35098167-C528E7D5-A813-4C20-A708-18784F221CBDQ35131913-45E14E32-619F-49D5-A76C-32CBB369B26DQ35568846-B5043786-86AE-42F6-9A83-184EF5D93B18Q35575320-A36FB8D1-ACA3-4BC2-AC2F-F63BBF26C0EEQ36631361-55DC1B73-5964-4A19-B37F-24DED0489940Q36886708-750D5D34-EF39-464E-BF17-ADA3B65EB390Q37659157-A96AA46E-0818-42A8-9D3C-99A192A2823CQ38172091-6677E366-8BBB-4259-9727-6857AB46CEF1Q38549796-EBF3C762-403D-416B-9271-E651141E33C2Q38871233-3A521DE2-458A-4182-BCD6-F7F147FED073Q38880522-222185A4-ABE3-4AF4-A669-58C922E3BF0DQ39206915-6520F9E5-AC71-4548-BE13-DA92E3948322Q40060340-BE75E626-0D38-405A-A1A1-F78C84273424Q40088340-08185E86-96F3-4C10-9A75-EB3C29F94660Q40377329-098882A6-D0AD-46A5-8860-FC93D6E58B84Q40454886-EFF2B8B6-AF13-43DB-A45E-97B0C6CA524CQ41676735-1DE66F69-79D4-4806-8866-E2B42C02F688Q41700108-8B808036-3F6B-4A28-AC91-E1DE59589CCEQ41703438-987C2263-7ABB-47AC-A92F-9086ED56D358Q42382708-A2D4739C-6AA0-45DA-82A8-65DB8FBBE042Q43017782-4C7C0966-2DA8-4530-8C6A-AAC166DDF997Q47372048-4C5533E9-CD31-425F-88E6-C4E19622B51CQ49546197-31565AEE-52E0-4096-A999-F047B08E5791Q49604618-8055B94A-2B48-49FF-9BE5-ED6C6BB976FF
P2860
Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes.
@ast
Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes.
@en
Aspergillosis in Intensive Care Unit
@nl
type
label
Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes.
@ast
Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes.
@en
Aspergillosis in Intensive Care Unit
@nl
prefLabel
Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes.
@ast
Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes.
@en
Aspergillosis in Intensive Care Unit
@nl
P2093
P2860
P356
P1476
Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes.
@en
P2093
Haran T Schlamm
Jennifer M Stephens
John W Baddley
Miriam Tarallo
P2860
P2888
P356
10.1186/1471-2334-13-29
P577
2013-01-23T00:00:00Z
P5875
P6179
1007988208